In summary, we revealed that miR‐192‐5p promotes GC EMT, thereby promoting malignancy and FOXP3+ Treg cell differentiation via RB1/NF‐κBp65/IL‐10 axis, thereby highlighting the miR‐192‐5p/RB1/NF‐κBp65/IL‐10 pathway as a new therapeutic strategy for tumour immunotherapy in GC. The gene discussed is IL10; the disease is neoplasm.